2024-02-28T22:08:38-08:00 2022-12-31 861778331 Archibald Advisory LLC 2961 E Cullumber St Gilbert AZ 85234 990 2022-01-01 770682420 INTL SOC FOR CARDIOVASCULAR TRAN RES INTL 4804385015 3104 E Camelback Road 564 Phoenix AZ 85016 DR NABIL DIB President 2024-02-28 true DR NABIL DIB 999009999 true Adam Brown P01866266 4808770021 0 AAL1 IAL1 FAL1 2022 2023-04-26 12:10:37Z DR NABIL DIB 3104 E Camelback Road 564 Phoenix AZ 85016 214457 false X N/A X 2007 CA TO PROVIDE AN ENVIRONMENT FOR COLLABORATION AND GUIDANCE AMONG BASIC AND CLINICAL SCIENTISTS, REGULATORY AUTHORITIES AND THE MEDICAL INDUSTRY TO EXPEDITE SCIENTIFIC DISCOVERIES INTO CLINICAL APPLICATIONS, DISSEMINATE THE SCIENCE AMONG THE SCIENTIFIC COMMUNITY, PROMOTE RESEARCH, DEVELOPMENT OF GUIDELINES FOR TRAINING AND CERTIFICATION IN TRANSLATIONAL RESEARCH, INFLUENCE HEALTH CARE POLICY, EDUCATE THE PUBLIC, AND IMPROVE THE WELL-BEING OF PATIENTS. 27 27 1 27 0 243500 161200 19823 50560 0 2697 263323 214457 0 0 89457 73750 0 11934 40433 174218 129890 247968 133433 -33511 530038 496527 0 530038 496527 TO PROVIDE AN ENVIRONMENT FOR COLLABORATION AND GUIDANCE AMONG BASIC AND CLINICAL SCIENTISTS, REGULATORY AUTHORITIES AND THE MEDICAL INDUSTRY TO EXPEDITE SCIENTIFIC DISCOVERIES INTO CLINICAL APPLICATIONS, DISSEMINATE THE SCIENCE AMONG THE SCIENTIFIC COMMUNITY, PROMOTE RESEARCH, DEVELOPMENT OF GUIDELINES FOR TRAINING AND CERTIFICATION IN TRANSLATIONAL RESEARCH, INFLUENCE HEALTH CARE POLICY, EDUCATE THE PUBLIC, AND IMPROVE THE WELL-BEING OF PATIENTS. false false 195958 51618 A summit, corresponding online courses, and an online journal, intended for physicians, medical device engineers, industry personnel, regulatory agencies, hospital administration, and reimbursement agencies titled, Translational Pathways for Cardiovascular Devices with the objective To Present and Discuss the Translational Pathways for Cardiovascular Diagnostic and Therapeutic Devices that Incorporates Input from Academia, Industry, FDA, and Payers. The sections included: 1. Device development processes, 2. Advances in high-risk coronary lesions, 3. Structural heart intervention Imaging, 4. Left appendage closure devices, 5. Pathways for heart failure, 6. Complex coronary occlusions. 195958 true true false false false false false false false false true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true 2 0 false 1 true false false false false false false false 0 false false false false false false false X 27 27 false false false false false false false true false false false true true true true true true true true false CA X DR NABIL DIB 4804385015 3420 S MERCY RD 312 GILBERT AZ 85297 SPENCER KING III Chairman 1.00 0.00 X X 4799 0 0 ROBERT BONOW Director 1.00 0.00 X 0 0 0 SCOTT WARD Director 1.00 0.00 X 0 0 0 STANTON ROWE Director 1.00 0.00 X 0 0 0 CHARLES SIMONTON Director 1.00 0.00 X 0 0 0 DANIEL BURKHOFF Director 1.00 0.00 X 0 0 0 STUART FLYNN Director 1.00 0.00 X 0 0 0 STEFANIE DIMMELER Director 1.00 0.00 X 0 0 0 MAGDI YACOUB Director 1.00 0.00 X 0 0 0 PETER BARCA Secretary 1.00 0.00 X X 0 0 0 DR NABIL DIB President 20.00 0.00 X X 0 0 0 OLIVER HARPER Director 1.00 0.00 X 0 0 0 ROBERT ROBERTS Chairman 1.00 0.00 X X 0 0 0 ANTHONY DEMARIA Vice President 1.00 0.00 X X 0 0 0 DAVID HOLMES Director 1.00 0.00 X 0 0 0 MITCHELL KRUCOFF Director 1.00 0.00 X 0 0 0 LOUIS JACQUES Director 1.00 0.00 X 0 0 0 JEROEN BAX Director 1.00 0.00 X 0 0 0 PIETER KAPPETEIN Director 1.00 0.00 X 0 0 0 MARTIN LEON Director 1.00 0.00 X 0 0 0 BRAM ZUCKERMAN Director 1.00 0.00 X 0 0 0 RON WAKSMAN Director 1.00 0.00 X 0 0 0 ALAIN CRIBIER Director 1.00 0.00 X 0 0 0 IAN MEREDITH Director 1.00 0.00 X 0 0 0 TODD BRINTON Director 1.00 0.00 X 0 0 0 JOHN LASCHINGER Director 1.00 0.00 X 0 0 0 Thomas Luscher Director 1.00 0.00 X 0 0 0 4799 0 false false false 0 161200 161200 ISCTR Medical Journal 513120 13118 13118 Online Classes 611600 37442 37442 50560 0 0 0 0 0 0 0 0 Federal Refund 1639 1639 Miscellaneous Income 1058 1058 2697 214457 51618 1639 0 0 0 0 4799 4799 0 56542 28271 22617 5654 0 49 25 20 4 12360 6180 4944 1236 0 1117 1117 633 633 0 0 0 18938 15421 2474 1043 26962 22918 2696 1348 4062 3453 406 203 6175 5866 309 0 1262 1073 126 63 37656 32007 3766 1883 0 51960 51960 0 0 20742 20742 0 DUES & SUBSCRIPTIONS 3222 2739 322 161 Taxes and Fees 896 896 Meals 593 504 59 30 0 247968 195958 40076 11934 337488 324719 0 0 0 0 0 0 0 0 8374 6546 2560 1828 0 0 0 189990 169980 0 530038 496527 0 0 X 530038 496527 530038 496527 530038 496527 -33511 X false false false X 595287 620558 296195 243500 161200 1916740 0 0 595287 620558 296195 243500 161200 1916740 354211 1562529 7683 7683 0 1162 2697 3859 1928282 79068 0.81030 0.89250 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 8374 6546 1828 1828 Form 990, Part VI, Section B, Line 11b THE TAX RETURN INFORMATION IS GATHERED BY STAFF AND LEGAL COUNSEL. THE INFORMATION IS REVIEWED BY THE STAFF AND PROVIDED TO AN ACCOUNTING FIRM THAT PREPARES THE TAX RETURNS. AN INITIAL DRAFT OF THE FORM 990 IS SUBMITTED TO THE CEO AND LEGAL COUNSEL FOR REVIEW. COMMENTS FROM THOSE INDIVIDUALS ARE CONSIDERED AND INCORPORATED INTO A REVISED DRAFT THAT IS PRESENTED TO THE BOARD OF DIRECTORS PRIOR TO FILING. THE BOARD OF DIRECTORS REVIEWS THE REVISED DRAFT AND SUBMITS COMMENTS TO THE CEO. COMMENTS FROM THOSE INDIVIDUALS ARE COMMUNICATED TO THE TAX PREPARER. Form 990, Part VI, Section B, Line 12c EACH BOARD MEMBER, OFFICER OF THE CORPORATION AND BOARD COMMITTEE MEMBER COMPLETES A CONFLICT OF INTEREST DISCLOSURE STATEMENT ANNUALLY. THE CEO ALONG WITH GENERAL COUNSEL EXAMINES EACH DISCLOSURE STATEMENT WHERE POTENTIAL CONFLICTS HAVE BEEN DISCLOSED. RECOMMENDATIONS ARE MADE TO THE CHAIR OF THE BOARD ON HOW TO APPROPRIATELY DISCLOSE. RECOMMENDATIONS ARE MADE TO THE CHAIR OF THE BOARD ON HOW TO APPROPRIATELY REMEDIATE, MONITOR, OR ELIMINATE ANY CONFLICTS. THE CEO THEN PROVIDES TO THE INTERESTED PERSON, WITH COPIES TO THE CHAIR, THE CEO, AND, IF NEEDED, THE APPROPRIATE COMMITTEE CHAIR, CORRESPONDENCE THAT SPECIFIES WHAT ACTIONS, CONDITION, OR MONITORING OF THE CONFLICT ARE REQUIRED AND WHETHER THE INTERESTED PERSON IS PERMITTED TO GIVE A PRESENTATION TO THE BOARD OR APPROPRIATE COMMITTEE AFTER FULL DISCLOSURE OF THE CONFLICT. IN SUCH AN EVENT, THE INTERESTED PERSON LEAVES THE MEETING WHILE THE PROPOSED TRANSACTION IS DISCUSSED. IF A CONFLICT OR FINANCIAL INTEREST ARISES AFTER THE ANNUAL DISCLOSURE PROCESS, THE INTERESTED PERSON WILL CONSULT WITH THE COMPLIANCE 0FFICE OR GENERAL COUNSEL AND WILL UPDATE THE DISCLOSURE STATEMENT CONSISTENT WITH THE ADVICE OF THE GENERAL COUNSEL. A RECORD OF THE BOARD OR COMMITTEE MEETING WHERE PROPOSED TRANSACTIONS OR ARRANGEMENTS THAT ARE AFFECTED BY CONFLICT OF INTEREST AND THE MANAGEMENT OF SUCH ARE CONTAINED IN THE BOARD/COMMITTEE MINUTES. Form 990, Part VI, Section B, Line 15a THE CORPORATION HAS ADOPTED A COMPENSATION POLICY WHICH REQUIRES THE CORPORATION TO ESTABLISH ALL COMPENSATION UNDER IRS GUIDELINES TO ENSURE THAT COMPENSATION IS LIMITED TO REASONABLE COMPENSATION FOR THE TYPE AND AMOUNT OF SERVICES PERFORMED BY THE EMPLOYEE, HIS OR HER RELEVANT BACKGROUND, EXPERIENCE, AND EDUCATION, AND IN LIGHT OF ANY OTHER RELEVANT FACTORS, AS WELL AS BASED ON DATA AVAILABLE ON COMPENSATION PAID BY SIMILARLY SITUATED ORGANIZATIONS FOR SIMILAR SERVICES. THE BOARD WILL ALSO FOLLOW ITS CONFLICTS OF INTEREST POLICY, IF APPLICABLE APPROVE COMPENSATION PRIOR TO PAYING IT, AND DOCUMENT IN WRITING THE APPROVED TERMS AND CONDITIONS AND WHAT INFORMATION WAS USED TO DETERMINE THE COMPENSATION. Form 990, Part VI, Section C, Line 19 DOCUMENTS ARE AVAILABLE UPON REQUEST FOR A NOMINAL FEE FOR COPYING COSTS.